Both isotretinoin and ATRA are capable of binding to RAR receptors (44, 45), including RARA, which is driven by a super-enhancer during ATRA treatment and is highly expressed as a functional member of the retino-sympathetic CRC. This evidence concerns the gene RARA and colorectal carcinoma.